Matched marrow and blood profiling reveals compartment- and feature-specific liquid-biopsy signals in multiple myeloma
Abelman, D. D.; Eagles, J.; Pedersen, S.; Scott, D. S.; Danesh, A.; Bruce, J. P.; Prokopec, S. D.; Wong, A.; Wei, E. N.; Shah, S.; White, D.; Sandhu, I.; Song, K.; Murugesan, A.; Reiman, A.; Trudel, S.; Pugh, T. J.
Show abstract
Multiple myeloma is bone-marrow-predominant, motivating marrow plasma cell-free DNA (cfDNA) as a tumor-proximal liquid biopsy. We tested whether marrow plasma cfDNA better represents the myeloma genome than peripheral blood cfDNA by profiling matched marrow plasma cells and both cfDNA compartments from 74 patients across 372 cfDNA sample time points. Tumor fractions correlated between compartments (r=0.84), but marrow plasma cfDNA was not a superior surrogate: peripheral-blood cfDNA matched or exceeded marrow-plasma cfDNA for marrow-defined CNA and mutation recovery (77.4% vs 72.0%; 69.2% vs 65.4%), with high specificity. Disease-associated features were detected in 69/74 peripheral-blood and 68/74 marrow-plasma profiles. BCR clonotypes were the highest-recovery feature, with BM-dominant clonotypes recovered in 31/34 callable profiles per compartment. At high tumor fraction, adverse-lesion sensitivity reached 100% in both cfDNA compartments. Marrow plasma cfDNA showed distinct, handling-sensitive fragmentomic architecture (LOOCV AUC=0.910), demonstrating performance depends on compartment, biomarker class, tumor fraction and processing context.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Multiple Myeloma DREAM Challenge Reveals Epigenetic Regulator PHF19 As Marker of Aggressive Disease 94%
- Clinical Impact of Panel Based Error Corrected Next Generation Sequencing versus Flow Cytometry to Detect Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) 92%
- A three-dimensional ex vivo model recapitulates in vivo features and unravels increased drug resistance in childhood acute lymphoblastic leukemia 91%
Similar papers in this journal
- Accelerated single cell seeding in relapsed multiple myeloma 94%
- Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes 92%
- Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma 91%
Similar papers in this journal
- Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry 92%
- High WEE1 expression is independently linked to poor survival in multiple myeloma 91%
- Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality 90%
Similar papers in this journal
- A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma 93%
- Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia 90%
- Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer 89%
Similar papers in this journal
- Impact of clonal architecture on clinical course and prognosis in patients with myeloproliferative neoplasms 92%
- IntegrateALL: an end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL 91%
- Ex Vivo Drug Responses and Molecular Profiles of 597 Pediatric Acute Lymphoblastic Leukemia Patients 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.